Peter Anastasiou
Direktor/Vorstandsmitglied bei HARMONY BIOSCIENCES HOLDINGS, INC.
Aktive Positionen von Peter Anastasiou
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
HARMONY BIOSCIENCES HOLDINGS, INC. | Direktor/Vorstandsmitglied | 05.11.2023 | - |
Independent Dir/Board Member | 05.11.2023 | - | |
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Direktor/Vorstandsmitglied | 01.07.2017 | - |
Capsida Biotherapeutics, Inc.
Capsida Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capsida Biotherapeutics, Inc. engages in the development of gene therapies for life threatening genetic disorders. It focuses on the provision of adeno-associated virus engineering platform to generate targeted gene therapies. The company is headquartered in Westlake Village, CA. | Direktor/Vorstandsmitglied | 01.01.2022 | - |
Vorstandsvorsitzender | 01.01.2022 | - |
Karriereverlauf von Peter Anastasiou
Ehemalige bekannte Positionen von Peter Anastasiou
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
H. LUNDBECK A/S | Corporate Officer/Principal | 01.01.2009 | 31.12.2021 |
ALDER BIOPHARMACEUTICALS, INC. | Präsident | - | - |
BRISTOL-MYERS SQUIBB COMPANY | Vertrieb & Marketing | - | - |
ELI LILLY AND COMPANY | Corporate Officer/Principal | - | - |
NEURONETICS, INC. | Vertrieb & Marketing | 10.04.2006 | - |
Ausbildung von Peter Anastasiou
Albion College | Undergraduate Degree |
Kelley School of Business | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 10 |
Dänemark | 2 |
Operativ
Director/Board Member | 3 |
Sales & Marketing | 2 |
Corporate Officer/Principal | 2 |
Sektoral
Health Technology | 8 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 5 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
ELI LILLY AND COMPANY | Health Technology |
H. LUNDBECK A/S | Health Technology |
NEURONETICS, INC. | Health Technology |
HARMONY BIOSCIENCES HOLDINGS, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Health Technology |
Lundbeck Seattle BioPharmaceuticals, Inc.
Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Capsida Biotherapeutics, Inc.
Capsida Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capsida Biotherapeutics, Inc. engages in the development of gene therapies for life threatening genetic disorders. It focuses on the provision of adeno-associated virus engineering platform to generate targeted gene therapies. The company is headquartered in Westlake Village, CA. | Commercial Services |
- Börse
- Insiders
- Peter Anastasiou
- Erfahrung